Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2006 1
2007 4
2008 1
2009 8
2010 15
2011 14
2012 23
2013 41
2014 34
2015 22
2016 15
2017 9
2018 3
2019 6
2020 2
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 22517061

174 results
Results by year
Filters applied: . Clear all
Page 1
Clinical grand rounds: atypical hemolytic uremic syndrome.
Hodgkins KS, Bobrowski AE, Lane JC, Langman CB. Hodgkins KS, et al. Am J Nephrol. 2012;35(5):394-400. doi: 10.1159/000337954. Epub 2012 Apr 18. Am J Nephrol. 2012. PMID: 22517061 Free article.
Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome.
Diamante Chiodini B, Davin JC, Corazza F, Khaldi K, Dahan K, Ismaili K, Adams B. Diamante Chiodini B, et al. Pediatrics. 2014 Jun;133(6):e1764-8. doi: 10.1542/peds.2013-1594. Pediatrics. 2014. PMID: 24843055
Eculizumab as first-line therapy for atypical hemolytic uremic syndrome.
Christmann M, Hansen M, Bergmann C, Schwabe D, Brand J, Schneider W. Christmann M, et al. Pediatrics. 2014 Jun;133(6):e1759-63. doi: 10.1542/peds.2013-1787. Pediatrics. 2014. PMID: 24843059
Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.
Xie L, Nester CM, Reed AI, Zhang Y, Smith RJ, Thomas CP. Xie L, et al. Transplant Proc. 2012 Dec;44(10):3037-40. doi: 10.1016/j.transproceed.2012.07.141. Transplant Proc. 2012. PMID: 23195022
Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy.
Fakhouri F, Frémeaux-Bacchi V, Loirat C. Fakhouri F, et al. Eur J Intern Med. 2013 Sep;24(6):492-5. doi: 10.1016/j.ejim.2013.05.008. Epub 2013 Jun 5. Eur J Intern Med. 2013. PMID: 23756030 Review.
Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation.
Zuber J, Le Quintrec M, Krid S, Bertoye C, Gueutin V, Lahoche A, Heyne N, Ardissino G, Chatelet V, Noël LH, Hourmant M, Niaudet P, Frémeaux-Bacchi V, Rondeau E, Legendre C, Loirat C; French Study Group for Atypical HUS. Zuber J, et al. Am J Transplant. 2012 Dec;12(12):3337-54. doi: 10.1111/j.1600-6143.2012.04252.x. Epub 2012 Sep 7. Am J Transplant. 2012. PMID: 22958221 Free article.
Complement inhibitor eculizumab in atypical hemolytic uremic syndrome.
Mache CJ, Acham-Roschitz B, Frémeaux-Bacchi V, Kirschfink M, Zipfel PF, Roedl S, Vester U, Ring E. Mache CJ, et al. Clin J Am Soc Nephrol. 2009 Aug;4(8):1312-6. doi: 10.2215/CJN.01090209. Epub 2009 Jun 25. Clin J Am Soc Nephrol. 2009. PMID: 19556379 Free PMC article.
Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor B.
Gilbert RD, Fowler DJ, Angus E, Hardy SA, Stanley L, Goodship TH. Gilbert RD, et al. Pediatr Nephrol. 2013 Aug;28(8):1315-8. doi: 10.1007/s00467-013-2492-x. Epub 2013 Apr 28. Pediatr Nephrol. 2013. PMID: 23624872
Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome.
Weitz M, Amon O, Bassler D, Koenigsrainer A, Nadalin S. Weitz M, et al. Pediatr Nephrol. 2011 Aug;26(8):1325-9. doi: 10.1007/s00467-011-1879-9. Epub 2011 May 10. Pediatr Nephrol. 2011. PMID: 21556717
Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab.
Schmidtko J, Peine S, El-Housseini Y, Pascual M, Meier P. Schmidtko J, et al. Am J Kidney Dis. 2013 Feb;61(2):289-99. doi: 10.1053/j.ajkd.2012.07.028. Epub 2012 Nov 7. Am J Kidney Dis. 2013. PMID: 23141475 Review.
174 results
Jump to page
Feedback